Top Markets
#1 GEKKO GEKKO +51.79%
#2 Helium Helium +45.36%
#3 ADO Protocol ADO Protocol +38.91%
#4 Prom Prom +34.97%
#5 Pons Pons +33.94%
#6 TENDIES TENDIES +31.01%
#7 Collector Crypt Collector Crypt +28.01%
#8 StonkBroker StonkBroker +26.08%
#9 Collect on Fanable Collect on Fanable +20.42%
#10 Cysic Cysic +20.13%
Coin of the day
GEKKO GEKKO
Settings
Language
ENGLISH
Currency
USD
Theme
Lepu Biopharma Co., Ltd. Lepu Biopharma Co., Ltd.

Lepu Biopharma Co., Ltd.

2157
Rank in Stocks #9736
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise,... Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
Share Price
$0.53025422
Last synced: 2026-08-28
Market Cap
$956.81M
Change (1 day)
0.61%
Change (1 year)
-52.36%
Country
CN
Trade Lepu Biopharma Co., Ltd. (2157)

Category

Healthcare
Revenue for Lepu Biopharma Co., Ltd. (2157)
Revenue in Aug 2026 TTM: 0
According to Lepu Biopharma Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Lepu Biopharma Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH